{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:13:26Z","timestamp":1791216806751,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s11886-016-0745-6","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T09:07:31Z","timestamp":1464080851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?"],"prefix":"10.1007","volume":"18","author":[{"given":"Geesje M.","family":"Dallinga-Thie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"745_CR1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626\u201335.","journal-title":"Lancet"},{"key":"745_CR2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299\u2013308.","journal-title":"JAMA"},{"key":"745_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309\u201316.","journal-title":"JAMA"},{"key":"745_CR4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","volume":"34","author":"AB Jorgensen","year":"2013","unstructured":"Jorgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826\u201333.","journal-title":"Eur Heart J"},{"key":"745_CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","volume":"3","author":"JE Hokanson","year":"1996","unstructured":"Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213\u20139.","journal-title":"J Cardiovasc Risk"},{"key":"745_CR6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336. This excellent paper describes the association between plasma levels of remnant cholesterol and ischemic heart disease in a large population cohort in Denmark and illustrates the importance of remnant cholesterol in the pathokogy of CVD.","journal-title":"J Am Coll Cardiol"},{"key":"745_CR7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10654-010-9501-1","volume":"25","author":"AS Lindman","year":"2010","unstructured":"Lindman AS, Veierod MB, Tverdal A, et al. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur J Epidemiol. 2010;25:789\u201398.","journal-title":"Eur J Epidemiol"},{"key":"745_CR8","first-page":"2499","volume":"307","author":"C Emerging Risk Factors","year":"2012","unstructured":"Emerging Risk Factors C, Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499\u2013506.","journal-title":"JAMA"},{"key":"745_CR9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345\u201361. This is an important paper describing new guidelines with regard to the treatment of patients with elevated levels of remnant cholesterol and triglycerides.","journal-title":"Eur Heart J"},{"key":"745_CR10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352.","journal-title":"Nat Genet"},{"key":"745_CR11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36:539\u201350.","journal-title":"Eur Heart J"},{"key":"745_CR12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","volume":"375","author":"C Triglyceride Coronary Disease Genet","year":"2010","unstructured":"Triglyceride Coronary Disease Genetics C, Emerging Risk Factors C, Sarwar N, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634\u20139.","journal-title":"Lancet"},{"key":"745_CR13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2:655\u201366. This is an overview of all the current knowledge.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"745_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0b013e3283471972","volume":"22","author":"CT Johansen","year":"2011","unstructured":"Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol. 2011;22:247\u201353.","journal-title":"Curr Opin Lipidol"},{"key":"745_CR15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000084","volume":"25","author":"MM Hussain","year":"2014","unstructured":"Hussain MM. Intestinal lipid absorption and lipoprotein formation. Curr Opin Lipidol. 2014;25:200\u20136.","journal-title":"Curr Opin Lipidol"},{"key":"745_CR16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0033-1358519","volume":"33","author":"DE Cohen","year":"2013","unstructured":"Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis. 2013;33:380\u20138.","journal-title":"Semin Liver Dis"},{"key":"745_CR17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cmet.2007.02.002","volume":"5","author":"AP Beigneux","year":"2007","unstructured":"Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5:279\u201391.","journal-title":"Cell Metab"},{"key":"745_CR18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cmet.2014.01.017","volume":"19","author":"CN Goulbourne","year":"2014","unstructured":"Goulbourne CN, Gin P, Tatar A, et al. The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab. 2014;19:849\u201360.","journal-title":"Cell Metab"},{"key":"745_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cmet.2010.04.016","volume":"12","author":"BS Davies","year":"2010","unstructured":"Davies BS, Beigneux AP, Barnes 2nd RH, et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 2010;12:42\u201352.","journal-title":"Cell Metab"},{"key":"745_CR20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/phrs.2001.0871","volume":"44","author":"JC Fruchart","year":"2001","unstructured":"Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res. 2001;44:345\u201352.","journal-title":"Pharmacol Res"},{"key":"745_CR21","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","volume":"15","author":"K Schoonjans","year":"1996","unstructured":"Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336\u201348.","journal-title":"EMBO J"},{"key":"745_CR22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.atherosclerosis.2016.01.010","volume":"246","author":"C Caussy","year":"2016","unstructured":"Caussy C, Charriere S, Meirhaeghe A, et al. Multiple microRNA regulation of lipoprotein lipase gene abolished by 3\u2019UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter. Atherosclerosis. 2016;246:280\u20136.","journal-title":"Atherosclerosis"},{"key":"745_CR23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbrc.2011.09.120","volume":"414","author":"J Ahn","year":"2011","unstructured":"Ahn J, Lee H, Chung CH, Ha T. High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. Biochem Biophys Res Commun. 2011;414:664\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"745_CR24","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","volume":"297","author":"H Wang","year":"2009","unstructured":"Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297:E271\u2013288.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"745_CR25","first-page":"919","volume":"2014","author":"S Kersten","year":"1841","unstructured":"Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta. 1841;2014:919\u201333.","journal-title":"Biochim Biophys Acta"},{"key":"745_CR26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","volume":"272","author":"RP Surendran","year":"2012","unstructured":"Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272:185\u201396.","journal-title":"J Intern Med"},{"key":"745_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-291X(70)90468-7","volume":"41","author":"JC LaRosa","year":"1970","unstructured":"LaRosa JC, Levy RI, Herbert P, et al. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun. 1970;41:57\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"745_CR28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.metabol.2011.12.002","volume":"61","author":"AA Kei","year":"2012","unstructured":"Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61:906\u201321.","journal-title":"Metabolism"},{"key":"745_CR29","doi-asserted-by":"crossref","first-page":"18029","DOI":"10.1074\/jbc.M114.629865","volume":"290","author":"NL Meyers","year":"2015","unstructured":"Meyers NL, Larsson M, Olivecrona G, Small DM. A pressure-dependent model for the regulation of lipoprotein lipase by apolipoprotein C-II. J Biol Chem. 2015;290:18029\u201344.","journal-title":"J Biol Chem"},{"key":"745_CR30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.114.220418","volume":"352","author":"MJ Amar","year":"2015","unstructured":"Amar MJ, Sakurai T, Sakurai-Ikuta A, et al. A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther. 2015;352:227\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"745_CR31","doi-asserted-by":"crossref","unstructured":"Sakurai T, Sakurai A, Vaisman BL et al. Creation of ApoC-II mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide. J Pharmacol Exp Ther. 2016;356:341\u2013353.","DOI":"10.1124\/jpet.115.229740"},{"key":"745_CR32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MOL.0b013e32832b3f4c","volume":"20","author":"JD Sparks","year":"2009","unstructured":"Sparks JD, Dong HH. FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol. 2009;20:217\u201326.","journal-title":"Curr Opin Lipidol"},{"key":"745_CR33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","volume":"26","author":"FM Sacks","year":"2015","unstructured":"Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26:56\u201363.","journal-title":"Curr Opin Lipidol"},{"key":"745_CR34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cmet.2011.11.005","volume":"14","author":"AG Holleboom","year":"2011","unstructured":"Holleboom AG, Karlsson H, Lin RS, et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab. 2011;14:811\u20138.","journal-title":"Cell Metab"},{"key":"745_CR35","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702\u20135.","journal-title":"Science"},{"key":"745_CR36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/CIRCGENETICS.113.000369","volume":"7","author":"DC Crawford","year":"2014","unstructured":"Crawford DC, Dumitrescu L, Goodloe R, et al. Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the Epidemiologic Architecture for Genes Linked to Environment Study. Circ Cardiovasc Genet. 2014;7:848\u201353.","journal-title":"Circ Cardiovasc Genet"},{"key":"745_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB Jorgensen","year":"2014","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341.","journal-title":"N Engl J Med"},{"key":"745_CR38","doi-asserted-by":"crossref","unstructured":"TG, HDL Working Group of the Exome Sequencing Project NHL, Blood I, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22\u201331.","DOI":"10.1056\/NEJMoa1307095"},{"key":"745_CR39","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2015.08.866","volume":"66","author":"P Natarajan","year":"2015","unstructured":"Natarajan P, Kohli P, Baber U, et al. Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis: The Multi-Ethnic BioImage Study. J Am Coll Cardiol. 2015;66:2053\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"745_CR40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","volume":"30","author":"CO Mendivil","year":"2010","unstructured":"Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:239\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR41","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","volume":"288","author":"M Larsson","year":"2013","unstructured":"Larsson M, Vorrsjo E, Talmud P, et al. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013;288:33997\u20134008.","journal-title":"J Biol Chem"},{"key":"745_CR42","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200\u20136.","journal-title":"N Engl J Med"},{"key":"745_CR43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/ATVBAHA.110.221846","volume":"31","author":"HN Ginsberg","year":"2011","unstructured":"Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol. 2011;31:471\u20133.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00125-006-0261-0","volume":"49","author":"GM Dallinga-Thie","year":"2006","unstructured":"Dallinga-Thie GM, van Tol A, Hattori H, et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:1505\u201311.","journal-title":"Diabetologia"},{"key":"745_CR45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","volume":"518","author":"R Do","year":"2015","unstructured":"Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518:102\u20136.","journal-title":"Nature"},{"key":"745_CR46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ng.628","volume":"42","author":"CT Johansen","year":"2010","unstructured":"Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet. 2010;42:684\u20137.","journal-title":"Nat Genet"},{"key":"745_CR47","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1194\/jlr.M500533-JLR200","volume":"47","author":"FG Schaap","year":"2006","unstructured":"Schaap FG, Nierman MC, Berbee JF, et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res. 2006;47:2333\u20139.","journal-title":"J Lipid Res"},{"key":"745_CR48","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1194\/jlr.M600233-JLR200","volume":"47","author":"SF Vaessen","year":"2006","unstructured":"Vaessen SF, Schaap FG, Kuivenhoven JA, et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res. 2006;47:2064\u201370.","journal-title":"J Lipid Res"},{"key":"745_CR49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MOL.0b013e32835c8c1a","volume":"24","author":"V Sharma","year":"2013","unstructured":"Sharma V, Forte TM, Ryan RO. Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Curr Opin Lipidol. 2013;24:153\u20139.","journal-title":"Curr Opin Lipidol"},{"key":"745_CR50","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/ATVBAHA.110.210815","volume":"30","author":"X Shu","year":"2010","unstructured":"Shu X, Nelbach L, Weinstein MM, et al. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav\u2212\/\u2212 mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol. 2010;30:2504\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/ATVBAHA.110.214718","volume":"31","author":"P Gin","year":"2011","unstructured":"Gin P, Beigneux AP, Voss C, et al. Binding preferences for GPIHBP1, a glycosylphosphatidylinositol-anchored protein of capillary endothelial cells. Arterioscler Thromb Vasc Biol. 2011;31:176\u201382.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tcm.2007.10.003","volume":"18","author":"T Hato","year":"2008","unstructured":"Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 2008;18:6\u201314.","journal-title":"Trends Cardiovasc Med"},{"key":"745_CR53","doi-asserted-by":"crossref","first-page":"E1299","DOI":"10.1210\/jc.2015-1254","volume":"100","author":"PA Nidhina Haridas","year":"2015","unstructured":"Nidhina Haridas PA, Soronen J, Sadevirta S, et al. Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin. J Clin Endocrinol Metab. 2015;100:E1299\u20131307.","journal-title":"J Clin Endocrinol Metab"},{"key":"745_CR54","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.0604026103","volume":"103","author":"V Sukonina","year":"2006","unstructured":"Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S A. 2006;103:17450\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"745_CR55","doi-asserted-by":"crossref","first-page":"28524","DOI":"10.1074\/jbc.M113.497602","volume":"288","author":"MJ Lafferty","year":"2013","unstructured":"Lafferty MJ, Bradford KC, Erie DA, Neher SB. Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J Biol Chem. 2013;288:28524\u201334.","journal-title":"J Biol Chem"},{"key":"745_CR56","doi-asserted-by":"crossref","first-page":"11865","DOI":"10.1074\/jbc.M114.623769","volume":"290","author":"X Chi","year":"2015","unstructured":"Chi X, Shetty SK, Shows HW, et al. Angiopoietin-like 4 modifies the interactions between lipoprotein lipase and its endothelial cell transporter GPIHBP1. J Biol Chem. 2015;290:11865\u201377.","journal-title":"J Biol Chem"},{"key":"745_CR57","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220\u20137.","journal-title":"N Engl J Med"},{"key":"745_CR58","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.bbrc.2012.12.025","volume":"430","author":"Z Fu","year":"2013","unstructured":"Fu Z, Yao F, Abou-Samra AB, Zhang R. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem Biophys Res Commun. 2013;430:1126\u201331.","journal-title":"Biochem Biophys Res Commun"},{"key":"745_CR59","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","volume":"109","author":"F Quagliarini","year":"2012","unstructured":"Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109:19751\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"745_CR60","first-page":"1207","volume":"48","author":"A Hiukka","year":"2005","unstructured":"Hiukka A, Fruchart-Najib J, Leinonen E, et al. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetes. 2005;48:1207\u201315.","journal-title":"Diabetes"},{"key":"745_CR61","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1161\/ATVBAHA.111.224808","volume":"31","author":"MR Taskinen","year":"2011","unstructured":"Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144\u201350.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/er.2014-1062","volume":"36","author":"GF Lewis","year":"2015","unstructured":"Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36:131\u201347.","journal-title":"Endocr Rev"},{"key":"745_CR63","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","volume":"28","author":"M Adiels","year":"2008","unstructured":"Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225\u201336.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","volume":"49","author":"M Adiels","year":"2006","unstructured":"Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755\u201365.","journal-title":"Diabetologia"},{"key":"745_CR65","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1007\/s00125-007-0790-1","volume":"50","author":"M Adiels","year":"2007","unstructured":"Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia. 2007;50:2356\u201365.","journal-title":"Diabetologia"},{"key":"745_CR66","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/ATVBAHA.115.305614","volume":"35","author":"J Boren","year":"2015","unstructured":"Boren J, Watts GF, Adiels M, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol. 2015;35:2218\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","volume":"239","author":"MR Taskinen","year":"2015","unstructured":"Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483\u201395. Excellent review on the underlying pathophysiology of the dyslipidemia in type 2 diabetes mellitus.","journal-title":"Atherosclerosis"},{"key":"745_CR68","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1161\/ATVBAHA.111.224808","volume":"31","author":"MR Taskinen","year":"2011","unstructured":"Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144\u201350.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","volume":"36","author":"GD Norata","year":"2015","unstructured":"Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36:675\u201387.","journal-title":"Trends Pharmacol Sci"},{"key":"745_CR70","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","volume":"78","author":"HN Ginsberg","year":"1986","unstructured":"Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287\u201395.","journal-title":"J Clin Invest"},{"key":"745_CR71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","volume":"31","author":"MJ Chapman","year":"2010","unstructured":"Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149\u201364.","journal-title":"Eur Heart J"},{"key":"745_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.numecd.2011.09.007","volume":"22","author":"P Fogelstrand","year":"2012","unstructured":"Fogelstrand P, Boren J. Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. Nutr Metab Cardiovasc Dis. 2012;22:1\u20137.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"745_CR73","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIRCRESAHA.115.307182","volume":"117","author":"ED Bartels","year":"2015","unstructured":"Bartels ED, Christoffersen C, Lindholm MW, Nielsen LB. Altered metabolism of LDL in the arterial wall precedes atherosclerosis regression. Circ Res. 2015;117:933\u201342.","journal-title":"Circ Res"},{"key":"745_CR74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cvr\/cvv218","volume":"108","author":"SM Armstrong","year":"2015","unstructured":"Armstrong SM, Sugiyama MG, Fung KY, et al. A novel assay uncovers an unexpected role for SR-BI in LDL transcytosis. Cardiovasc Res. 2015;108:268\u201377.","journal-title":"Cardiovasc Res"},{"key":"745_CR75","doi-asserted-by":"crossref","first-page":"C242","DOI":"10.1152\/ajpcell.00185.2008","volume":"295","author":"PG Frank","year":"2008","unstructured":"Frank PG, Pavlides S, Cheung MW, et al. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol. 2008;295:C242\u2013248.","journal-title":"Am J Physiol Cell Physiol"},{"key":"745_CR76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","volume":"431","author":"J Boren","year":"2014","unstructured":"Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014;431:131\u201342.","journal-title":"Clin Chim Acta"},{"key":"745_CR77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/joim.12071","volume":"274","author":"J Boren","year":"2013","unstructured":"Boren J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med. 2013;274:25\u201340.","journal-title":"J Intern Med"},{"key":"745_CR78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","volume":"417","author":"K Skalen","year":"2002","unstructured":"Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750\u20134.","journal-title":"Nature"},{"key":"745_CR79","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.ATV.0000117174.19078.85","volume":"24","author":"C Flood","year":"2004","unstructured":"Flood C, Gustafsson M, Pitas RE, et al. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol. 2004;24:564\u201370.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR80","doi-asserted-by":"crossref","first-page":"32228","DOI":"10.1074\/jbc.M204053200","volume":"277","author":"C Flood","year":"2002","unstructured":"Flood C, Gustafsson M, Richardson PE, et al. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem. 2002;277:32228\u201333.","journal-title":"J Biol Chem"},{"key":"745_CR81","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1172\/JCI2265","volume":"101","author":"J Boren","year":"1998","unstructured":"Boren J, Olin K, Lee I, et al. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998;101:2658\u201364.","journal-title":"J Clin Invest"},{"key":"745_CR82","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/01.RES.33.6.633","volume":"33","author":"DB Zilversmit","year":"1973","unstructured":"Zilversmit DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res. 1973;33:633\u20138.","journal-title":"Circ Res"},{"key":"745_CR83","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","volume":"60","author":"DB Zilversmit","year":"1979","unstructured":"Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473\u201385.","journal-title":"Circulation"},{"key":"745_CR84","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/S0022-2275(20)35345-1","volume":"34","author":"JS Cohn","year":"1993","unstructured":"Cohn JS, Johnson EJ, Millar JS, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 1993;34:2033\u201340.","journal-title":"J Lipid Res"},{"key":"745_CR85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/01.ATV.15.2.199","volume":"15","author":"F Karpe","year":"1995","unstructured":"Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol. 1995;15:199\u2013207.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"745_CR86","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.90.5.2069","volume":"90","author":"BO Schneeman","year":"1993","unstructured":"Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993;90:2069\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"745_CR87","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2012.02.001","volume":"222","author":"M Adiels","year":"2012","unstructured":"Adiels M, Matikainen N, Westerbacka J, et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis. 2012;222:222\u20138.","journal-title":"Atherosclerosis"},{"key":"745_CR88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1126\/science.106.2748.190","volume":"106","author":"JR Moreton","year":"1947","unstructured":"Moreton JR. Atherosclerosis and alimentary hyperlipidemia. Science. 1947;106:190\u20131.","journal-title":"Science"},{"key":"745_CR89","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.107.2780.371","volume":"107","author":"JR Moreton","year":"1948","unstructured":"Moreton JR. Physical state of lipids and foreign substances producing atherosclerosis. Science. 1948;107:371\u20133.","journal-title":"Science"},{"key":"745_CR90","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","volume":"300","author":"JJ Freiberg","year":"2008","unstructured":"Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300:2142\u201352.","journal-title":"JAMA"},{"key":"745_CR91","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2013.05.064","volume":"62","author":"H Beltran-Sanchez","year":"2013","unstructured":"Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999\u20132010. J Am Coll Cardiol. 2013;62:697\u2013703.","journal-title":"J Am Coll Cardiol"},{"key":"745_CR92","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"745_CR93","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2014.08.007","volume":"20","author":"JC Cohen","year":"2014","unstructured":"Cohen JC, Stender S, Hobbs HH. APOC3, coronary disease, and complexities of Mendelian randomization. Cell Metab. 2014;20:387\u20139.","journal-title":"Cell Metab"},{"key":"745_CR94","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell 3rd TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479\u201390.","journal-title":"Circ Res"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-016-0745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-016-0745-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-016-0745-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T05:13:10Z","timestamp":1656565990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-016-0745-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s11886-016-0745-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]},"article-number":"67"}}